CORDIS · 261468 · FP7
MABSOT Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation
Coordinator: OPSONA THERAPEUTICS LIMITED (IE)
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare diseases, particularly those of genetic origin, are associated with the requirement for solid organ transplantation as the disease progresses. At Opsona Therapeutics we have developed a novel antibody (OP…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
EU contribution: €5.9M awarded to the consortium. The project runs over approximately 3.8 years from 2010-12-01 to 2014-09-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from IE
see all →- MSCA4Ukraine — MSCA4Ukraine101101923 · HORIZON · €35.0M
- WaterLANDS — Water-based solutions for carbon storage, people and wilderness101036484 · H2020 · €23.1M
- INFRACHIP — European Research Infrastructure on Semiconductor Chips101131822 · HORIZON · €14.5M
- PRIMES — PRIMES: Protein interaction machines in oncogenic EGF receptor signalling278568 · FP7 · €12.0M
- NAMDIATREAM — NANOTECHNOLOGICAL TOOLKITS FOR MULTI-MODAL DISEASE DIAGNOSTICS AND TREATMENT MONITORING246479 · FP7 · €12.0M
- REALLOCATE — Rethinking the dEsign of streets And pubLic spaces to Leverage the mOdal shift to Climate-friendly Active Transport Everywhere101103924 · HORIZON · €12.0M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the CP-FP funding scheme.
- What is the EU contribution?
- The European Commission contributes €5.9M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by OPSONA THERAPEUTICS LIMITED (IE).
- What is the project timeline?
- The project runs from 2010-12-01 to 2014-09-30 — approximately 3.8 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 261468.